Publication
Serum Galectin-3 as a complementary biomarker in non-muscle-invasive bladder cancer.
Recep Eryılmaz, Muhammed Fatih Keleş, Rahmi Aslan, Zübeyir Huyut, Murat Demir, Kasım Ertaş, Mehmet Sevim, Kerem Taken
Urologic oncologySep 26, 2026PMID 42800378doi:10.1016/j.urolonc.2026.08.027 Journal ArticlepubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 29, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260929-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
OBJECTIVE: To evaluate serum Galectin-3 levels in patients with non-muscle-invasive bladder cancer (NMIBC) and to investigate their diagnostic performance and ability to discriminate between low-grade and high-grade disease. METHODS: This prospective controlled study included 80 patients with NMIBC…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Bladder Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available
No curated evidence item cites this publication.